For NSCLC patients whose tumors have high PD-L1 expression, overall survival (OS) and progression-free survival (PFS) of patients treated by immune checkpoint inhibitor are thought to be superior to first-line chemotherapy regimens [7]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.